Therefore, our results only serve as a platform for future trials on new-generation ALKIs as first-line therapy for advanced ALK-positive NSCLC patients, not as direct evidence to promote any single agent as a frontline option at present. The gene discussed is ALK; the disease is non-small cell lung carcinoma.